Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK.

J Clin Oncol. 2011 Jun 1;29(16):2259-65. doi: 10.1200/JCO.2010.32.6397. Epub 2011 May 2.

PMID:
21537039
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
[PubMed - indexed for MEDLINE]
3.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

PMID:
17346499
[PubMed - indexed for MEDLINE]
Free Article
4.

Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.

de Gramont A, Van Cutsem E.

Oncology. 2005;69 Suppl 3:46-56. Epub 2005 Nov 21. Review.

PMID:
16301835
[PubMed - indexed for MEDLINE]
5.

Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

Buie LW, Valgus J.

Ann Pharmacother. 2008 Oct;42(10):1486-90. doi: 10.1345/aph.1L030. Epub 2008 Sep 2. Review.

PMID:
18765835
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk